Skip to main content
OpenTrials
Completed

NCT Number: NCT00308347

A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)

Evaluate the effect of Losartan in reducing kidney disease in patients with Non-insulin Dependent Diabetes and Nephropathy (kidney damage that usually accompanies late stage Diabetes Mellitus).

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diabetes diagnosed after the age of 30
  • Insulin not required within 6 months of first being diagnosed with Non-insulin Dependent Diabetes Mellitus
  • No history of diabetic ketoacidosis
  • Patients may be currently treated with diet, oral hypoglycemics or insulin
  • Patients must have proteinuria defined as: Urine protein >1+ on dipstick at the initial screening visit
  • Patients with hypertension (high blood pressure) must have a sitting blood pressure >200/110 mm Hg at Visit 1

Exclusion criteria

  • Patients with insulin-dependent diabetes mellitus (juvenile onset)
  • Patients treated with an ACE inhibitor or angiotensin II antagonist (AIIA) for >5 years
  • Patients treated with ACE inhibitor or AIIA therapy for 5 years or less may enter the study provided therapy is discontinued during the 6 week screening period prior to randomization
  • History of myocardial infarction (MI) (heart attack) or coronary artery bypass graft (CABG) surgery within the past 1 month
  • History of cerebral vascular accident (CVA) (stroke) or percutaneous transluminal coronary angioplasty (PTCA) within the past 6 months
  • History of transient ischemic attacks (TIA) within the past year. Patients with unstable angina are excluded until stabilized
  • Heart failure requiring ACE inhibitor therapy
  • Steroids (oral or parenteral) or immunosuppressives are not permitted. Debilitating psychological illness
  • Evidence of significant hepatic (liver) dysfunction: History of allergy to losartan
  • Known positive test for HIV or patients known to be hepatitis B or C antigen carriers
  • Pregnant or nursing women
  • Females of childbearing age must either be surgically sterilized or, if sexually active, using an effective form of contraception and may enter only if an exclusionary pregnancy test is done within approximately 72 hours prior to randomization
  • Pregnancy tests will be done every 3 months during the study and at the time of discontinuation

Treatment and study plan

MK0954, losartan / Duration of Treatment: mean 3.4 years

Drug

Placebo / Duration of Treatment: mean 3.4 years

Drug

Primary outcomes

  1. Combined endpoint of doubling of serum creatinine, ESRD or death.

Secondary outcomes

  1. Secondary parameters: number of cardiovascular events and changes in proteinuria. Tertiary parameters: quality of life and healthcare resource utilization.

Sponsors and collaborators

Lead sponsor

Organon and Co

Industry

Registry information

Official study title

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy

Important dates

Study start
1996
Primary completion
2001
Study completion
2001
First posted
Mar 29, 2006
Registry last updated
Feb 15, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.